Director & Founder, BenevolentAI
Ken Mulvany is a serial entrepreneur, investor and healthcare and technology veteran with more than 20 years of business leadership experience. He is currently a director at BenevolentAI, a technology company he founded in 2013, which is developing and using Artificial Intelligence (AI) to change the way knowledge is created and applied in life sciences. He was previously CEO of Proximagen, a UK-based biotech company committed to delivering novel drugs and innovative new treatments for central nervous system (CNS) disorders. Mulvany’s experience running a biotech, in an industry entirely reliant on scientific innovation, highlighted the challenge of trying to foster innovation when the processes for scientific discovery have not largely changed for 50 years. He recognized that we are facing a fundamental information bottleneck, as facts and information accumulates regardless of whether we can absorb them intellectually. He established BenevolentAI to change that.